Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer
暂无分享,去创建一个
M. Meyerson | G. Wei | A. Letai | L. Garraway | D. Bowtell | O. Cohen | C. Johannessen | Mukta Bagul | A. Cherniack | M. Rees | F. Piccioni | S. Pantel | A. Goodale | Yenarae Lee | U. Matulonis | J. Montero | J. Ryan | I. Zervantonakis | E. Christie | K. Sarosiek | P. Bhola | E. Stover | Cory M. Johannessen | Yvonne Y. Li | Jennifer L. Guerriero | Weiqun Zhang | Adam Presser | Maria B. Baco | Maya K. Gelbard | F. Liang | Adam G. Presser | Ofir Cohen | J. Ryan
[1] G. Mills,et al. Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness , 2019, Molecular Cancer Therapeutics.
[2] D. Root,et al. DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells , 2018, Nature.
[3] Ashton C. Berger,et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. , 2018, Cancer cell.
[4] E. Swisher,et al. Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. , 2018, Cell reports.
[5] Zhenfeng Zhang,et al. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors , 2018, Nature Communications.
[6] D. Root,et al. Pooled Lentiviral‐Delivery Genetic Screens , 2018, Current protocols in molecular biology.
[7] A. Leary,et al. 973PA GINECO phase II study of Navitoclax (ABT 263) in women with platinum resistant/refractory recurrent ovarian cancer (ROC) , 2017 .
[8] G. Mills,et al. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response , 2017, Nature Communications.
[9] E. Kohn,et al. Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP , 2017, International journal of oncology.
[10] A. Ashkenazi,et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors , 2017, Nature Reviews Drug Discovery.
[11] A. Strasser,et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models , 2016, Nature.
[12] D. Etemadmoghadam,et al. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition , 2016, Clinical Cancer Research.
[13] R. Tang,et al. BCL-W is a regulator of microtubule inhibitor-induced mitotic cell death , 2016, Oncotarget.
[14] A. Richardson,et al. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells , 2016, Journal of Ovarian Research.
[15] Meagan E. Sullender,et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.
[16] Joshua A. Bittker,et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action , 2015, Nature chemical biology.
[17] L. Wessels,et al. Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt‐based anti‐cancer drugs , 2015, The EMBO journal.
[18] G. Shapiro,et al. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. , 2015, Cancer discovery.
[19] C. Ricciardelli,et al. The role of ABC transporters in ovarian cancer progression and chemoresistance. , 2015, Critical reviews in oncology/hematology.
[20] Joshy George,et al. Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.
[21] Dolores Diaz,et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy , 2015, Science Translational Medicine.
[22] S. Lheureux,et al. Identification of predictive factors of response to the BH3‐mimetic molecule ABT‐737: An ex vivo experiment in human serous ovarian carcinoma , 2015, International journal of cancer.
[23] Michael R. Green,et al. Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4 , 2015, Genes & development.
[24] Karen Cichowski,et al. Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.
[25] Xian-Jin Xie,et al. Genome‐wide siRNA screen reveals coupling between mitotic apoptosis and adaptation , 2014, The EMBO journal.
[26] S. Lheureux,et al. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced. , 2014, Cancer letters.
[27] Mark E. Burkard,et al. Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles , 2014, Science Translational Medicine.
[28] A. Letai,et al. Mitochondria: gatekeepers of response to chemotherapy. , 2013, Trends in cell biology.
[29] C. Sander,et al. Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.
[30] A. Richardson,et al. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells. , 2013, Gynecologic oncology.
[31] S. Lheureux,et al. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis , 2013, Apoptosis.
[32] Andrew L. Kung,et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. , 2012, Cancer cell.
[33] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[34] F. Peale,et al. Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models , 2012, Molecular Cancer Therapeutics.
[35] A. Letai,et al. Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.
[36] R. Bast,et al. Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel. , 2011, Cancer research.
[37] Rochelle L. Garcia,et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Thomas M Green,et al. A public genome-scale lentiviral expression library of human ORFs , 2011, Nature Methods.
[39] Adam R. Johnson,et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 , 2011, Nature.
[40] Shilpi Arora,et al. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. , 2010, Gynecologic oncology.
[41] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[42] L. Poulain,et al. Bcl‐XL and MCL‐1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis , 2009, International journal of cancer.
[43] W. Wilson,et al. Ongoing phase I studies of ABT-263: Mitigating Bcl-XL induced thrombocytopenia with lead-in and continuous dosing. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] S. Kaye,et al. The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin , 2007, Clinical Cancer Research.
[45] A. Piché,et al. Bcl-XL is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells , 2006 .
[46] K. Griffith,et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. , 2005, Gynecologic oncology.
[47] O. Katoh,et al. Increased MCL–1 Expression Is Associated with Poor Prognosis in Ovarian Carcinomas , 2002, Japanese journal of cancer research : Gann.
[48] I. Nagata,et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. , 1999, European journal of cancer.
[49] S. Kassim,et al. Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer. , 1999, Clinical biochemistry.
[50] C. Hu,et al. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. , 1998, Gynecologic oncology.
[51] A. Piché,et al. Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells. , 2006, Gynecologic oncology.